Mrs Amanda Courtney Easterling, LPN | |
509 Bassfield Cemetery Rd, Bassfield, MS 39421-8906 | |
(228) 254-0976 | |
Not Available |
Full Name | Mrs Amanda Courtney Easterling |
---|---|
Gender | Female |
Speciality | Licensed Practical Nurse |
Location | 509 Bassfield Cemetery Rd, Bassfield, Mississippi |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083349062 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | P323190 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Amanda Courtney Easterling, LPN 509 Bassfield Cemetery Rd, Bassfield, MS 39421-8906 Ph: (228) 254-0976 | Mrs Amanda Courtney Easterling, LPN 509 Bassfield Cemetery Rd, Bassfield, MS 39421-8906 Ph: (228) 254-0976 |
News Archive
Practice makes perfect - or at least that's what we're told as we struggle through endless rounds of multiplication tables, goal kicks and piano scales - and it seems, based on the personal experience of many, to be true.
Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, a journal of the American Association for Cancer Research.
Although inflammatory bowel disease (IBD) [comprising mainly Crohn's disease (CD) and ulcerative colitis (UC)] is thought to affect about 150 000 people in the United Kingdom, the prevalence of severe IBD is not known. Mortality following hospitalization for IBD is significant but little has been reported on long-term follow-up.
Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs.
For children and adolescents with HIV infection, the recent Food and Drug Administration (FDA) approval of the use of raltegravir, an antiretroviral drug that slows the spread of HIV infection, offers a new weapon to treat HIV infection in children.
› Verified 5 days ago